Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01742299 · ClinicalTrials.gov registry record · Phase 4
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
A Phase 4 study of GIST and CML, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 4
- Development phase
- 155
- Enrollment target
- 20
- Study locations
NCT01742299 is a Phase 4 study of GIST and CML that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 155 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT01742299, a Phase 4 study of GIST and CML, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 155 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to allow continued use of imatinib in patients who are on imatinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and are benefiting from the treatment as judged by the investigator.
Conditions Studied
Interventions
- DRUG imatinib mesylate
Study Locations (20)
Other
- Novartis Investigative Site - Beijing
- Novartis Investigative Site - Beijing
- Novartis Investigative Site - Guangzhou
- Novartis Investigative Site - Shanghai
- Novartis Investigative Site - Helsinki
- Novartis Investigative Site - Lille
- Novartis Investigative Site - Pessac
- Novartis Investigative Site - Poitiers
- Novartis Investigative Site - Hong Kong
California
- University of California LA - Los Angeles
Illinois
- Northwestern University - Chicago
Maryland
- Sidney Kimmel CCC At JH - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Weill Cornell Medical Center - New York
Oregon
- Oregon Health Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2013-03-26 |
| Est. Completion | 2033-04-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01742299
The ClinicalTrials.gov registry entry for NCT01742299 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with GIST and CML appearing as the primary indexed condition, and to 1 intervention - of which imatinib mesylate is the first listed.
NCT01742299 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT01742299 about?
NCT01742299 is a clinical study titled "Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator". The purpose of this study is to allow continued use of imatinib in patients who are on imatinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and are benefiting from the treatment as judged by the investigator.
What is the current status of trial NCT01742299?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 155 participants. The study started on 2013-03-26. Estimated completion is 2033-04-21.
What conditions does trial NCT01742299 study?
This clinical trial studies the following conditions: GIST and CML.
What interventions are being tested in trial NCT01742299?
The interventions under investigation include: imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT01742299?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01742299 being conducted?
This trial has 20 study locations across California, Illinois, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.